{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:13:49Z","timestamp":1792073629929,"version":"4.4.0"},"reference-count":26,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2007,7,20]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in persistent, progressive, or recurrent mycosis fungoides or S\u00e9zary syndrome (MF\/SS) cutaneous t-cell lymphoma (CTCL) subtypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Patients with stage IB-IVA MF\/SS were treated with 400 mg of oral vorinostat daily until disease progression or intolerable toxicity in this open-label phase IIb trial ( NCT00091559 ). Patients must have received at least two prior systemic therapies at least one of which included bexarotene unless intolerable. The primary end point was the objective response rate (ORR) measured by the modified severity weighted assessment tool and secondary end points were time to response (TTR), time to progression (TTP), duration of response (DOR), and pruritus relief (\u2265 3-point improvement on a 10-point visual analog scale). Safety and tolerability were also evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy-four patients were enrolled, including 61 with at least stage IIB disease. The ORR was 29.7% overall; 29.5% in stage IIB or higher patients. Median TTR in stage IIB or higher patients was 56 days. Median DOR was not reached but estimated to be \u2265 185 days (34+ to 441+). Median TTP was 4.9 months overall, and \u2265 9.8 months for stage IIB or higher responders. Overall, 32% of patients had pruritus relief. The most common drug-related adverse experiences (AE) were diarrhea (49%), fatigue (46%), nausea (43%), and anorexia (26%); most were grade 2 or lower but those grade 3 or higher included fatigue (5%), pulmonary embolism (5%), thrombocytopenia (5%), and nausea (4%). Eleven patients required dose modification and nine discontinued due to AE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Oral vorinostat was effective in treatment refractory MF\/SS with an acceptable safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.2006.10.2434","type":"journal-article","created":{"date-parts":[[2007,6,18]],"date-time":"2007-06-18T21:14:32Z","timestamp":1182201272000},"page":"3109-3115","source":"Crossref","is-referenced-by-count":928,"title":["Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma"],"prefix":"10.1200","volume":"25","author":[{"given":"Elise A.","family":"Olsen","sequence":"first","affiliation":[{"name":"From Duke University, Durham, NC; Stanford University, Stanford, CA; Northwestern University, Chicago, IL; University of Colorado Health Sciences Center at Fitzsimons, Aurora, CO; Tufts-New England Medical Center, Boston, MA; Emory University, Atlanta, GA; Merck Research Laboratories, Upper Gwynedd, PA; and the M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youn H.","family":"Kim","sequence":"additional","affiliation":[{"name":"From Duke University, Durham, NC; Stanford University, Stanford, CA; Northwestern University, Chicago, IL; University of Colorado Health Sciences Center at Fitzsimons, Aurora, CO; Tufts-New England Medical Center, Boston, MA; Emory University, Atlanta, GA; Merck Research Laboratories, Upper Gwynedd, PA; and the M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Kuzel","sequence":"additional","affiliation":[{"name":"From Duke University, Durham, NC; Stanford University, Stanford, CA; Northwestern University, Chicago, IL; University of Colorado Health Sciences Center at Fitzsimons, Aurora, CO; Tufts-New England Medical Center, Boston, MA; Emory University, Atlanta, GA; Merck Research Laboratories, Upper Gwynedd, PA; and the M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa R.","family":"Pacheco","sequence":"additional","affiliation":[{"name":"From Duke University, Durham, NC; Stanford University, Stanford, CA; Northwestern University, Chicago, IL; University of Colorado Health Sciences Center at Fitzsimons, Aurora, CO; Tufts-New England Medical Center, Boston, MA; Emory University, Atlanta, GA; Merck Research Laboratories, Upper Gwynedd, PA; and the M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine M.","family":"Foss","sequence":"additional","affiliation":[{"name":"From Duke University, Durham, NC; Stanford University, Stanford, CA; Northwestern University, Chicago, IL; University of Colorado Health Sciences Center at Fitzsimons, Aurora, CO; Tufts-New England Medical Center, Boston, MA; Emory University, Atlanta, GA; Merck Research Laboratories, Upper Gwynedd, PA; and the M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sareeta","family":"Parker","sequence":"additional","affiliation":[{"name":"From Duke University, Durham, NC; Stanford University, Stanford, CA; Northwestern University, Chicago, IL; University of Colorado Health Sciences Center at Fitzsimons, Aurora, CO; Tufts-New England Medical Center, Boston, MA; Emory University, Atlanta, GA; Merck Research Laboratories, Upper Gwynedd, PA; and the M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley R.","family":"Frankel","sequence":"additional","affiliation":[{"name":"From Duke University, Durham, NC; Stanford University, Stanford, CA; Northwestern University, Chicago, IL; University of Colorado Health Sciences Center at Fitzsimons, Aurora, CO; Tufts-New England Medical Center, Boston, MA; Emory University, Atlanta, GA; Merck Research Laboratories, Upper Gwynedd, PA; and the M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Chen","sequence":"additional","affiliation":[{"name":"From Duke University, Durham, NC; Stanford University, Stanford, CA; Northwestern University, Chicago, IL; University of Colorado Health Sciences Center at Fitzsimons, Aurora, CO; Tufts-New England Medical Center, Boston, MA; Emory University, Atlanta, GA; Merck Research Laboratories, Upper Gwynedd, PA; and the M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin L.","family":"Ricker","sequence":"additional","affiliation":[{"name":"From Duke University, Durham, NC; Stanford University, Stanford, CA; Northwestern University, Chicago, IL; University of Colorado Health Sciences Center at Fitzsimons, Aurora, CO; Tufts-New England Medical Center, Boston, MA; Emory University, Atlanta, GA; Merck Research Laboratories, Upper Gwynedd, PA; and the M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Marie","family":"Arduino","sequence":"additional","affiliation":[{"name":"From Duke University, Durham, NC; Stanford University, Stanford, CA; Northwestern University, Chicago, IL; University of Colorado Health Sciences Center at Fitzsimons, Aurora, CO; Tufts-New England Medical Center, Boston, MA; Emory University, Atlanta, GA; Merck Research Laboratories, Upper Gwynedd, PA; and the M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Duvic","sequence":"additional","affiliation":[{"name":"From Duke University, Durham, NC; Stanford University, Stanford, CA; Northwestern University, Chicago, IL; University of Colorado Health Sciences Center at Fitzsimons, Aurora, CO; Tufts-New England Medical Center, Boston, MA; Emory University, Atlanta, GA; Merck Research Laboratories, Upper Gwynedd, PA; and the M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.3.779"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3502"},{"key":"R3","unstructured":"Bunn PA Jr, Lamberg SI: Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. Cancer Treat Rep 63:725,1979-728,"},{"key":"R4","unstructured":"Kim YH, Willemze R, Pimpinelli N, et al: TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood  [epub ahead of print on March 15, 2007]"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.118538"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.7.857"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.14.167"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"O'Connor OA: Developing new drugs for the treatment of lymphoma. Eur J Haematol 75:150,2005-158,  (suppl 66)","DOI":"10.1111\/j.1600-0609.2005.00470.x"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1038\/35106079"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1007\/PL00000896"},{"key":"R11","unstructured":"Butler LM, Agus DB, Scher HI, et al: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60:5165,2000-5170,"},{"key":"R12","unstructured":"Cohen LA, Marks PA, Rifkind RA, et al: Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors. Anticancer Res 22:1497,2002-1504,"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200111537"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23925.x"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Garcia-Manero G, Yang H, Sanchez-Gonzalez B, et al: Final results of a phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with leukemia and myelodysplastic syndrome. Blood 106:785a,2005,","DOI":"10.1182\/blood.V106.11.2801.2801"},{"key":"R16","unstructured":"Kelly WK, Richon VM, O'Connor O, et al: Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9:3578,2003-3588,"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.9679"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1802"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-025999"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.9.2456"},{"key":"R21","unstructured":"Ontak\u00ae (denileukin diftitox) product label details. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/onctools\/labels.cfm?GN=denileukin%20difitox"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.376"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2002.n.003"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-198610000-00005"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0511"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2095"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2006.10.2434","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T16:04:14Z","timestamp":1653494654000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2006.10.2434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,20]]},"references-count":26,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2007,7,20]]}},"alternative-id":["10.1200\/JCO.2006.10.2434"],"URL":"https:\/\/doi.org\/10.1200\/jco.2006.10.2434","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1089765.542900","asserted-by":"object"}]},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,20]]}}}